Signaturefd LLC Reduces Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Signaturefd LLC lessened its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 8.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 39,487 shares of the company’s stock after selling 3,838 shares during the quarter. Signaturefd LLC’s holdings in Takeda Pharmaceutical were worth $563,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Sage Rhino Capital LLC boosted its holdings in shares of Takeda Pharmaceutical by 7.6% in the third quarter. Sage Rhino Capital LLC now owns 11,751 shares of the company’s stock worth $182,000 after buying an additional 831 shares during the last quarter. Legacy Wealth Asset Management LLC boosted its holdings in shares of Takeda Pharmaceutical by 0.7% in the third quarter. Legacy Wealth Asset Management LLC now owns 124,967 shares of the company’s stock worth $1,933,000 after buying an additional 851 shares during the last quarter. Vestmark Advisory Solutions Inc. boosted its holdings in shares of Takeda Pharmaceutical by 1.4% in the third quarter. Vestmark Advisory Solutions Inc. now owns 63,630 shares of the company’s stock worth $984,000 after buying an additional 870 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Takeda Pharmaceutical by 5.7% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 16,433 shares of the company’s stock worth $254,000 after buying an additional 883 shares during the last quarter. Finally, Simplicity Solutions LLC boosted its holdings in shares of Takeda Pharmaceutical by 0.4% in the third quarter. Simplicity Solutions LLC now owns 213,515 shares of the company’s stock worth $3,303,000 after buying an additional 955 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

TAK opened at $13.23 on Thursday. The company has a current ratio of 1.06, a quick ratio of 0.55 and a debt-to-equity ratio of 0.64. The company has a market cap of $41.87 billion, a price-to-earnings ratio of 20.05, a PEG ratio of 3.79 and a beta of 0.53. The company’s 50 day moving average is $14.11 and its 200 day moving average is $14.22. Takeda Pharmaceutical Company Limited has a 12-month low of $13.11 and a 12-month high of $17.11.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.51 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. The company had revenue of $7.52 billion for the quarter. On average, equities research analysts predict that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.